BACKGROUND: Adiponectin and resistin are recently discovered adipokines that may provide a molecular link between adiposity and type 2 diabetes. OBJECTIVE: To evaluate whether total and high-molecular-weight adiponectin and resistin are associated with future risk for type 2 diabetes, independent of obesity and other known diabetes risk factors. DESIGN: Prospective, nested, case-control study. SETTING: United States. PARTICIPANTS: 1038 initially healthy women of the Nurses' Health Study who developed type 2 diabetes after blood sampling (1989 to 1990) through 2002 and 1136 matched control participants. MEASUREMENTS: Plasma concentrations of total and high-molecular-weight adiponectin and resistin. RESULTS: In multivariate models including body mass index, higher total and high-molecular-weight adiponectin levels were associated with a substantially lower risk for type 2 diabetes (odds ratio [OR] comparing the highest with the lowest quintiles, 0.17 [95% CI, 0.12 to 0.25] for total adiponectin and 0.10 [CI, 0.06 to 0.15] for high-molecular-weight adiponectin). A higher ratio of high-molecular-weight to total adiponectin was associated with a statistically significantly lower risk even after adjustment for total adiponectin (OR, 0.45 [CI, 0.31 to 0.65]). In the multivariate model without body mass index, higher resistin levels were associated with a higher risk for diabetes (OR, 1.68 [CI, 1.25 to 2.25]), but the association was no longer statistically significant after adjustment for body mass index (OR, 1.28 [CI, 0.93 to 1.76]). LIMITATION: The findings apply mainly to white women and could be partly explained by residual confounding from imperfectly measured or unmeasured variables. CONCLUSION: Adiponectin is strongly and inversely associated with risk for diabetes, independent of body mass index, whereas resistin is not. The ratio of high-molecular-weight to total adiponectin is related to risk for diabetes independent of total adiponectin, suggesting an important role of the relative proportion of high-molecular-weight adiponectin in diabetes pathogenesis.
BACKGROUND:Adiponectin and resistin are recently discovered adipokines that may provide a molecular link between adiposity and type 2 diabetes. OBJECTIVE: To evaluate whether total and high-molecular-weight adiponectin and resistin are associated with future risk for type 2 diabetes, independent of obesity and other known diabetes risk factors. DESIGN: Prospective, nested, case-control study. SETTING: United States. PARTICIPANTS: 1038 initially healthy women of the Nurses' Health Study who developed type 2 diabetes after blood sampling (1989 to 1990) through 2002 and 1136 matched control participants. MEASUREMENTS: Plasma concentrations of total and high-molecular-weight adiponectin and resistin. RESULTS: In multivariate models including body mass index, higher total and high-molecular-weight adiponectin levels were associated with a substantially lower risk for type 2 diabetes (odds ratio [OR] comparing the highest with the lowest quintiles, 0.17 [95% CI, 0.12 to 0.25] for total adiponectin and 0.10 [CI, 0.06 to 0.15] for high-molecular-weight adiponectin). A higher ratio of high-molecular-weight to total adiponectin was associated with a statistically significantly lower risk even after adjustment for total adiponectin (OR, 0.45 [CI, 0.31 to 0.65]). In the multivariate model without body mass index, higher resistin levels were associated with a higher risk for diabetes (OR, 1.68 [CI, 1.25 to 2.25]), but the association was no longer statistically significant after adjustment for body mass index (OR, 1.28 [CI, 0.93 to 1.76]). LIMITATION: The findings apply mainly to white women and could be partly explained by residual confounding from imperfectly measured or unmeasured variables. CONCLUSION:Adiponectin is strongly and inversely associated with risk for diabetes, independent of body mass index, whereas resistin is not. The ratio of high-molecular-weight to total adiponectin is related to risk for diabetes independent of total adiponectin, suggesting an important role of the relative proportion of high-molecular-weight adiponectin in diabetes pathogenesis.
Authors: F F M Fisher; M E Trujillo; W Hanif; A H Barnett; P G McTernan; P E Scherer; S Kumar Journal: Diabetologia Date: 2005-05-19 Impact factor: 10.122
Authors: S Goya Wannamethee; Gordon D O Lowe; Ann Rumley; Lynne Cherry; Peter H Whincup; Naveed Sattar Journal: Diabetes Care Date: 2007-02-23 Impact factor: 19.112
Authors: Barbora Vozarova de Courten; Mikako Degawa-Yamauchi; Robert V Considine; P Antonio Tataranni; Barbora Volarova de Courten Journal: Diabetes Date: 2004-05 Impact factor: 9.461
Authors: Robert C Kaplan; Gloria Y F Ho; XiaoNan Xue; Swapnil Rajpathak; Mary Cushman; Thomas E Rohan; Howard D Strickler; Philipp E Scherer; Kathryn Anastos Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-06 Impact factor: 4.254
Authors: Konstantinos N Aronis; Maria T Vamvini; John P Chamberland; Laura L Sweeney; Aoife M Brennan; Faidon Magkos; Christos S Mantzoros Journal: Metabolism Date: 2011-11-09 Impact factor: 8.694
Authors: Hyon-Suk Kim; Jaeseong Jo; Jung Eun Lim; Young Duk Yun; Soo Jin Baek; Tae-Yong Lee; Kap Bum Huh; Sun Ha Jee Journal: Endocrine Date: 2013-02-06 Impact factor: 3.633
Authors: Dawn Q Chong; Raaj S Mehta; Mingyang Song; Dmitriy Kedrin; Jeffrey A Meyerhardt; Kimmie Ng; Kana Wu; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Andrew T Chan Journal: Cancer Prev Res (Phila) Date: 2015-09-17
Authors: Jessica L Fargnoli; Teresa T Fung; Deanna M Olenczuk; John P Chamberland; Frank B Hu; Christos S Mantzoros Journal: Am J Clin Nutr Date: 2008-11 Impact factor: 7.045